Rein Therapeutics Inc.
04/27/2026 | Press release | Distributed by Public on 04/27/2026 04:53
Amendment to Annual Report (Form 10-K/A)
This Amendment No. 1 (this "Amendment") amends the Annual Report on Form 10-K for the year ended December 31, 2025 of Rein Therapeutics, Inc. filed with the Securities and Exchange Commission (the "SEC") on March 26, 2026 (the "Original Form 10-K"). The purpose of this Amendment is to amend Part III, Items 10 through 14, of the Original Form 10-K to include information previously omitted from the Original Form 10-K in reliance on General Instruction G(3) to the Annual Report on Form 10-K. Accordingly, Part III of the Original Form 10-K is hereby amended and restated as set forth below and the reference on the cover page of the Original Form 10-K to the incorporation by reference of our definitive proxy statement into Part III of the Original Form 10-K is hereby deleted.
In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), new certifications by our principal executive officer and principal financial officer are filed as exhibits to this Amendment under Item 15 of Part IV hereof, which has been amended to reflect the filing of these new certifications. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted.
Except as described above, no other changes have been made to the Original Form 10-K. The Original Form 10-K continues to speak as of the date of the Original Form 10-K, and we have not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Form 10-K, other than as expressly indicated in this Amendment.
Unless indicated otherwise, throughout this Amendment, references to "Rein," "Company," "we," "us" and "our" refer to Rein Therapeutics, Inc. and its subsidiaries, except where the context otherwise requires or indicates.
Rein Therapeutics Inc. published this content on April 27, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 27, 2026 at 10:54 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]